Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Celyad stock

Learn how to easily invest in Celyad stock.

Celyad is a biotechnology business based in the US. Celyad shares (CYAD) are listed on the NASDAQ and all prices are listed in US Dollars. Celyad employs 95 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy Celyad stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – CYAD. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Promoted for options trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Celyad stock price (NASDAQ: CYAD)

Use our graph to track the performance of CYAD stocks over time.

Celyad shares at a glance

Information last updated 2023-01-24.
Latest market close$1.29
52-week range$0.46 - $3.65
50-day moving average $0.99
200-day moving average $1.57
Wall St. target price$8.52
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.51

Buy Celyad stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Celyad stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Celyad price performance over time

Historical closes compared with the close of $1.29 from 2023-01-27

1 week (2023-01-24) -19.88%
1 month (2022-12-30) 161.66%
3 months (2022-10-31) 22.86%
6 months (2022-07-29) -24.56%
1 year (2022-01-31) -63.25%
2 years (2021-01-29) -84.00%
3 years (2020-01-31) 10.8
5 years (2018-01-30) 47.52

Celyad financials

Gross profit TTM $5,000
Return on assets TTM -29.33%
Return on equity TTM -92.64%
Profit margin 0%
Book value $1.36
Market capitalisation $37.2 million

TTM: trailing 12 months

Celyad share dividends

We're not expecting Celyad to pay a dividend over the next 12 months.

Celyad share price volatility

Over the last 12 months, Celyad's shares have ranged in value from as little as $0.46 up to $3.65. A popular way to gauge a stock's volatility is its "beta".

CYAD.US volatility(beta: 0.9)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celyad's is 0.8992. This would suggest that Celyad's shares are less volatile than average (for this exchange).

Celyad overview

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. .

Frequently asked questions

What percentage of Celyad is owned by institutions?
Currently 29.127% of Celyad shares are held by institutions.
How many people work for Celyad?
Latest data suggests 95 work at Celyad.
When does the fiscal year end for Celyad?
Celyad's fiscal year ends in December.
Where is Celyad based?
Celyad's address is: Axis Business Park, Mont-Saint-Guibert, Belgium, 1435
What is Celyad's ISIN number?
Celyad's international securities identification number is: US1512052002
What is Celyad's CUSIP number?
Celyad's Committee on Uniform Securities Identification Procedures number is: 151205200

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site